596
Views
15
CrossRef citations to date
0
Altmetric
Perspective

B-cell tolerance in transplantation: is repertoire remodeling the answer?

, , , , , & show all
Pages 703-723 | Published online: 10 Jan 2014

Figures & data

Figure 1. The naive pre-immune B-cell subsets with cell surface markers and B-lymphocyte stimulator family cytokine receptors.

BCR: B-cell receptor; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.

Figure 1. The naive pre-immune B-cell subsets with cell surface markers and B-lymphocyte stimulator family cytokine receptors.BCR: B-cell receptor; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.
Figure 2. B-cell development and selection checkpoints.

(A) Immature B cells have successfully rearranged their heavy and light chain immunoglobulin genes. During the BCR checkpoint, immature B cells that are engaged by high avidity antigens are induced to die, while those who do not, transit to the periphery and become transitional B cells. The continued survival of transitional B cells in the periphery is dictated by the availability of B-lymphocyte stimulator (BLyS) and relative BCR tonic signaling. (B) The frequency of developing B-cell survival is depicted here as ontogeny progresses across the BCR and peripheral selection checkpoints. At the BCR checkpoint (red line), only 10% of the immature B cells survive, while at the peripheral B-cell selection checkpoint (green line), approximately 30% of the remaining B cells become mature follicular B cells.

BCR: B-cell receptor; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.

Figure 2. B-cell development and selection checkpoints.(A) Immature B cells have successfully rearranged their heavy and light chain immunoglobulin genes. During the BCR checkpoint, immature B cells that are engaged by high avidity antigens are induced to die, while those who do not, transit to the periphery and become transitional B cells. The continued survival of transitional B cells in the periphery is dictated by the availability of B-lymphocyte stimulator (BLyS) and relative BCR tonic signaling. (B) The frequency of developing B-cell survival is depicted here as ontogeny progresses across the BCR and peripheral selection checkpoints. At the BCR checkpoint (red line), only 10% of the immature B cells survive, while at the peripheral B-cell selection checkpoint (green line), approximately 30% of the remaining B cells become mature follicular B cells.BCR: B-cell receptor; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.
Figure 3. B-lymphocyte stimulator family of cytokines and ligands.

(A) Cells producing BLyS and/or APRIL. (B) Relative binding affinities for each receptor–ligand combination are very similar. However, it is important to note that the primary BLyS receptor responsible for regulating pre-immune B-cell homeostasis is BR3.

APRIL: A proliferation-inducing ligand; BAFF: B-cell-activating factor; BCMA: B-cell maturation antigen; BLyS: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.

Figure 3. B-lymphocyte stimulator family of cytokines and ligands.(A) Cells producing BLyS and/or APRIL. (B) Relative binding affinities for each receptor–ligand combination are very similar. However, it is important to note that the primary BLyS receptor responsible for regulating pre-immune B-cell homeostasis is BR3.APRIL: A proliferation-inducing ligand; BAFF: B-cell-activating factor; BCMA: B-cell maturation antigen; BLyS: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.
Figure 4. Inter-/intra-cellular mechanisms of B-lymphocyte stimulator neutralization and anti-CD20 treatment.

(A) BLyS–BR3 binding and tonic BCR signaling promotes B-cell survival, while anti-BLyS treatment favors apoptotic signals. (B) Anti-CD20 (e.g., rituximab) causes B-cell death via three separate mechanisms. (C) Prosurvival signals are upregulated in the setting of downstream cross-talk after BCR crosslinking and BLyS–BR3 binding.

ADCC: Antibody-depedent cell-mediated cytotoxicity; BCR: B-cell receptor; BLys: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; CDC: Complement-dependent cytotoxicity; MAC: Membrane-attack complex.

Figure 4. Inter-/intra-cellular mechanisms of B-lymphocyte stimulator neutralization and anti-CD20 treatment.(A) BLyS–BR3 binding and tonic BCR signaling promotes B-cell survival, while anti-BLyS treatment favors apoptotic signals. (B) Anti-CD20 (e.g., rituximab) causes B-cell death via three separate mechanisms. (C) Prosurvival signals are upregulated in the setting of downstream cross-talk after BCR crosslinking and BLyS–BR3 binding.ADCC: Antibody-depedent cell-mediated cytotoxicity; BCR: B-cell receptor; BLys: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; CDC: Complement-dependent cytotoxicity; MAC: Membrane-attack complex.
Figure 5. Mainstay immunosuppression versus repertoire remodeling in solid organ transplantation.

(A) After standard immunotherapy, the alloreactive B-cell subset persists, producing donor-specific antibodies, and ultimately causing chronic allograft rejection. (B) In the B-cell repertoire remodeling scenario, the alloreactive B-cell subset of the pre-immune B-cell repertoire is eliminated after B-cell depletion therapy. Induction T-cell depletion therapy is also given. Following transplantation, the B-cell repertoire undergoes reconstitution in the presence of alloantigens permitting clonal deletion of the alloreactive subset under B-lymphocyte stimulator-limiting conditions. In the absence of donor-specific B cells, allograft survival may improve.

Figure 5. Mainstay immunosuppression versus repertoire remodeling in solid organ transplantation.(A) After standard immunotherapy, the alloreactive B-cell subset persists, producing donor-specific antibodies, and ultimately causing chronic allograft rejection. (B) In the B-cell repertoire remodeling scenario, the alloreactive B-cell subset of the pre-immune B-cell repertoire is eliminated after B-cell depletion therapy. Induction T-cell depletion therapy is also given. Following transplantation, the B-cell repertoire undergoes reconstitution in the presence of alloantigens permitting clonal deletion of the alloreactive subset under B-lymphocyte stimulator-limiting conditions. In the absence of donor-specific B cells, allograft survival may improve.
Figure 6. B-lymphocyte stimulator levels (red) determine peripheral B-cell selection stringency and the number of B cells (blue).

(A) After rituximab induction therapy, B cells are depleted and BLyS levels rise, risking the development of alloreactive B cells upon reconstitution. (B) A similar scenario occurs with anti-BLyS induction. (C) Maintenance anti-BLyS following B-cell depletion creates BLyS-limiting conditions that minimize the risk of developing alloreactive B cells and antibody-mediated rejection.

Figure 6. B-lymphocyte stimulator levels (red) determine peripheral B-cell selection stringency and the number of B cells (blue).(A) After rituximab induction therapy, B cells are depleted and BLyS levels rise, risking the development of alloreactive B cells upon reconstitution. (B) A similar scenario occurs with anti-BLyS induction. (C) Maintenance anti-BLyS following B-cell depletion creates BLyS-limiting conditions that minimize the risk of developing alloreactive B cells and antibody-mediated rejection.
Figure 7. Antigen-experienced B-cell subsets with cell surface markers and B-lymphocyte stimulator family cytokine receptors.

BCMA: B-cell maturation antigen; BLyS: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; GC: Germinal center; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.

Figure 7. Antigen-experienced B-cell subsets with cell surface markers and B-lymphocyte stimulator family cytokine receptors.BCMA: B-cell maturation antigen; BLyS: B-lymphocyte stimulator; BR3: B-lymphocyte stimulator receptor 3; GC: Germinal center; TACI: Transmembrane activator 1 and calcium-signaling modulator and cyclophilin ligand-interactor.

Table 1. Summary of B-cell tolerance-promoting strategies/agents.

Table 2. Potential agents for treating antibody-mediated rejection and/or the presensitized patient.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.